Michael Schmitz
Stock Analyst at Guggenheim
(1.38)
# 3,435
Out of 4,947 analysts
7
Total ratings
50%
Success rate
-0.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Buy | $45 | $38.47 | +16.97% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $36.02 | +127.65% | 2 | Oct 28, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $66.94 | +65.82% | 2 | Oct 1, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $7.08 | +464.97% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.07 | - | 1 | Jan 3, 2023 |
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $38.47
Upside: +16.97%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $36.02
Upside: +127.65%
Merus
Oct 1, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $66.94
Upside: +65.82%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $7.08
Upside: +464.97%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.07
Upside: -